MindMed Inc.


Company Logo

Company Overview

Mind Medicine (MindMed) Inc. is a neuro-pharmaceutical company that discovers, develops and deploys psychedelic inspired medicines to improve health, promote wellness and alleviate suffering.

The company’s immediate priority is to address the opioid crisis by developing a non-hallucinogenic version of the psychedelic ibogaine. In addition, the company has established a microdosing division to conduct clinical trials of LSD microdosing for Adult ADHD, is pursuing experiential psychedelic assisted therapy for the treatment of anxiety, and is collaborating on a clinical trial to evaluate LSD for the treatment of cluster cluster headaches.

The MindMed executive team brings extensive biopharmaceutical industry experience to this groundbreaking approach to the development of next-generation psychedelic medicines. 

Financial Highlights


Revenue (ttm)


Gross Profit (ttm)


Diluted EPS (ttm)

Management Team

Mr. Jamon Alexander Rahn
Co-Founder, CEO & Director

Dr. Miriam Halperin Wernli
Exec. Pres & Director

Dr. Scott M. Freeman
Co-Founder & Clinical Advisor

Mr. Leonard Latchman

Mr. David Dean Guebert
Chief Financial Officer

Ms. Carol Nast
Chief Operating Officer

Mr. Bradford Cross
Chief Technology Officer

Dr. Donald R. Gehlert Ph.D.
Chief Scientific Officer & Member of Scientific Advisory Board

Ms. Madeline Feldman
Director of Operations & Admin.

Mr. Collin Gage
VP of Corp. Devel.

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Company Profile




Key Highlights

Market Capitalization

Shares Outstanding

Shares Short (% of Float)

Insider Ownership